| Identification | Back Directory | [Name]
SRI-29329 | [CAS]
2086809-58-5 | [Synonyms]
SRI-29329
9H-Purine-2,6-diamine, N2-[(1S,2S)-2-aminocyclohexyl]-N6-(3-chlorophenyl)-9-(1-methylethyl)- | [Molecular Formula]
C20H26ClN7 | [MDL Number]
MFCD32899878 | [MOL File]
2086809-58-5.mol | [Molecular Weight]
399.92 |
| Hazard Information | Back Directory | [Biological Activity]
SRI-29329 is a specific CLK inhibitor, with IC50 values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively[1].
SRI-29329 (compound 8) shows some modest (~5 fold) selectivity for CLK2 over CLK1 and CLK4 without significant CDK1,4,6 activity[1]. | [References]
[1]. Yihui Shi, et al. A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorg Med Chem Lett. 2017 Feb 1;27(3):406-412. |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|